Analyst Price Targets — TEM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 2:01 pm | Daniel Arias | Stifel Nicolaus | $60.00 | $53.83 | StreetInsider | Tempus AI Inc (TEM) PT Lowered to $60 at Stifel, Firm Highlights 'Solid' Outlook |
| February 19, 2026 10:00 am | Bradley Bowers | Mizuho Securities | $100.00 | $56.16 | TheFly | Tempus AI initiated with an Outperform at Mizuho |
| February 17, 2026 10:10 am | — | Robert W. Baird | $59.00 | $51.95 | TheFly | Tempus AI initiated with an Outperform at Baird |
| December 22, 2025 12:01 pm | Kyle Mikson | Canaccord Genuity | $80.00 | $64.46 | TheFly | Tempus AI price target lowered to $80 from $95 at Canaccord |
| December 1, 2025 9:34 pm | — | Morgan Stanley | $85.00 | $74.07 | TheFly | Tempus AI assumed with an Overweight at Morgan Stanley |
| November 25, 2025 11:14 am | Mark Massaro | BTIG | $105.00 | $76.06 | StreetInsider | Tempus AI Inc (TEM) PT Raised to $105 at BTIG |
| November 5, 2025 6:52 am | Kyle Mikson | Canaccord Genuity | $95.00 | $84.49 | StreetInsider | Tempus AI Inc (TEM) PT Lowered to $95 at Canaccord Genuity |
| October 22, 2025 10:30 am | — | Piper Sandler | $105.00 | $89.10 | TheFly | Tempus AI price target raised to $105 from $70 at Piper Sandler |
| October 20, 2025 9:34 am | — | Canaccord Genuity | $110.00 | $87.78 | TheFly | Tempus AI initiated with a Buy at Canaccord |
| September 26, 2025 11:25 am | — | Guggenheim | $95.00 | $78.93 | TheFly | Tempus AI price target raised to $95 from $80 at Guggenheim |
Latest News for TEM
Since going public in mid-2024, shares of healthcare and life science services company Tempus AI NASDAQ: TEM have gone on a wild rollercoaster ride. The firm's initial public offering price was $37.
Dakota Wealth Management lessened its position in Tempus AI, Inc. (NASDAQ: TEM) by 75.8% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 13,184 shares of the company's stock after selling 41,388 shares during the quarter. Dakota Wealth Management's holdings in Tempus
In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulatory challenges without losing sight of broader industry shifts.
Tempus AI maintains strong Q4 momentum, with robust testing stats and improving financials despite recent post-earnings stock weakness. Oncology testing volume grew 29% YoY, and net revenue retention reached 126%, signaling strong customer value and recurring demand. Adjusted EBITDA turned positive in Q4, and 2026 guidance projects $65M adjusted EBITDA, though revenue growth is expected to slow to 25%.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST. The live webcast may be accessed directly using…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TEM.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.